Gold Nanoparticle Based Platforms for Circulating Cancer Marker Detection.

Gold Nanoparticle Based Platforms for Circulating Cancer Marker Detection.
复制标题

DOI:
10.7150/ntno.18216
复制
发表时间:
2017
期刊:
影响因子:
--
通讯作者:
Kwizera EA
Kwizera EA
中科院分区:
其他
文献类型:
--
作者:
Huang X;O'Connor R;Kwizera EA

文献摘要

被引文献

相似文献

检测体液中与癌症相关的循环生物标志物已成为一项前沿技术,具有无创筛查癌症、早期诊断癌症、监测肿瘤进展和评估治疗反应的潜力。传统的分子和细胞检测方法要么对早期癌症干预不敏感,要么技术上昂贵且复杂,使得它们对于典型的临床环境不切实际。由于其特殊的结构和功能特性,无法从散装材料或离散分子,纳米技术正在开辟新的视野,低成本,快速,高灵敏度和高特异性检测循环癌症标志物。金纳米粒子具有合成简单、表面化学性质简单、生物相容性好、结构和环境敏感等优点,是一种独特的循环生物标志物检测的纳米平台。在这篇综述中,我们介绍了目前基于金纳米颗粒的技术平台,用于检测循环肿瘤标志物的四个主要类别-循环肿瘤细胞,囊泡,核酸和蛋白质。这些技术将在信号检测策略方面进行总结。提供了独特的例子,以突出国家的最先进的技术,显着推进基础和临床癌症研究。
Detection of cancer-related circulating biomarkers in body fluids has become a cutting-edge technology that has the potential to noninvasively screen cancer, diagnose cancer at early stage, monitor tumor progression, and evaluate therapy responses. Traditional molecular and cellular detection methods are either insensitive for early cancer intervention or technically costly and complicated making them impractical for typical clinical settings. Due to their exceptional structural and functional properties that are not available from bulk materials or discrete molecules, nanotechnology is opening new horizons for low cost, rapid, highly sensitive, and highly specific detection of circulating cancer markers. Gold nanoparticles have emerged as a unique nanoplatform for circulating biomarker detection owning to their advantages of easy synthesis, facile surface chemistry, excellent biocompatibility, and remarkable structure and environment sensitive optical properties. In this review, we introduce current gold nanoparticle-based technology platforms for the detection of four major classes of circulating cancer markers - circulating tumor cells, vesicles, nucleic acids, and proteins. The techniques will be summarized in terms of signal detection strategies. Distinctive examples are provided to highlight the state-of-the-art technologies that significantly advance basic and clinical cancer research.